USANA Health Sciences Q1 2025 Earnings Report

USANA Health Sciences EPS Results

• Actual EPS: $0.73
• Consensus EPS: $0.70
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: $0.86

USANA Health Sciences Revenue Results

• Actual Revenue: $249.54 million
• Expected Revenue: $243.08 million
• Beat/Miss: Beat by +$6.46 million
• YoY Revenue Growth: N/A

USANA Health Sciences Announcement Details

• Quarter: Q1 2025
• Date: 4/22/2025
• Time: After Market Closes
• Conference Call Date: Wednesday, April 23, 2025
• Conference Call Time: 11:00AM ET

USANA Health Sciences (NYSE:USNA) develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

USANA Health Sciences Q1 2025 Earnings Call Transcript

Key Takeaways

• Solid Q1 sales growth: Consolidated net sales rose 12% year-over-year in constant currency, including a 64% sequential increase in both net sales and active customers in Mainland China.
• Associate-first momentum: Leadership events across multiple markets—highlighted by a high-attendance China National Sales Meeting in Nanjing—bolstered engagement, training, and product introductions.
• Product innovation pipeline: Several new products rolled out in Q1 with additional launches planned in the second half, backed by CSO-led market visits to gather customer feedback on future ideas.
• HYA acquisition integration: Hyatt delivered strong sales and subscriber growth, led by faster-than-expected adoption of Kids Daily Greens, with further product launches, partnerships, and channel expansion scheduled.
• Tariff mitigation strategies: No tariff impacts are included in guidance as USANA builds safety stock, pursues alternate sourcing, and leverages its China-for-China and US-for-rest-of-the-world manufacturing structure.

Presentation

[Operator]

Greetings. Welcome to the USANA Health Sciences First Quarter Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the presentation. Please note that this conference is being recorded.

[Operator]

I will now turn the conference over to your host, Andrew Masuda, Director, Investor Relations. Thank you. You may begin.

[Andrew Masuda, Director of Investor Relations at USANA Health Sciences]

Thank you, Diego, and good morning, everyone. We appreciate you joining us to review our first quarter results. Today's conference call is being broadcast live via webcast and can be accessed directly from our website at ir.usana.com. Shortly following the call, a replay will be available on our website. As a reminder, during the course of this conference call, management will make forward looking statements regarding future events or the future financial performance of our company.

[Andrew Masuda, Director of Investor Relations at USANA Health Sciences]

Those statements involve risks and uncertainties that could cause actual results to differ, perhaps materially, from the results projected in such forward looking statements. Examples of these statements include those regarding our strategies and outlook for fiscal year twenty twenty five, uncertainty related to the economic and operating environment around the world and our operations and financial results. We caution you that these statements should be considered in conjunction with disclosures, including specific risk factors and financial data contained in our most recent filings with the SEC. I'm joined by our President and CEO, Jim Brown our Chief Financial Officer, Doug Hekking our Chief Operating Officer, Walter Note our Chief Commercial Officer, Brent Nydig as well as other executives. Yesterday, after the market closed, we announced our first quarter results and posted our management commentary document on the company's website.

[Andrew Masuda, Director of Investor Relations at USANA Health Sciences]

We'll now hear brief remarks from Jim before opening the call for questions.

[Jim Brown, CEO & President at USANA Health Sciences]

Thank you, Andrew, and good morning, everyone. USANA is off to a solid start to the year. Our first quarter results were in line with our internal expectations as consolidated net sales grew 12% year over year in constant currency, which includes our first full quarter of contribution from Hyatt. Net sales and active customers in our direct selling in active For example, sequential first quarter net sales and active customers in our largest market, Mainland China, grew 64% respectively. We continue to execute our associate first strategy that prioritizes associate engagement on multiple levels. Accordingly, we held several leadership events across various markets during the quarter and have many events planned throughout the remainder of the year. Early in the second quarter, we hosted our China National Sales Meeting in Nanjing, China.

[Jim Brown, CEO & President at USANA Health Sciences]

Attendance was strong while we focused on business building, strategy and training, leadership recognition and USANA's associate first commitment. We also used this event to broaden our product offering in China with the introduction of additional products. Both attendees and our executive team came away from this event energized and motivated. We also successfully expanded our product offering in several other markets with the rollout of new products during the first quarter. Simultaneously, the team continued to increase their efforts on several new product launches that are planned to be announced in the second half of the year.

[Jim Brown, CEO & President at USANA Health Sciences]

For instance, Doctor. Katherine Armstrong, our Chief Scientific Officer traveled to several of our Asia Pacific markets where she met with leaders and our local management teams to gather valuable insights and customer feedback as well as collaborate on future product ideas. Overall, our direct selling business remains on track to meet the sales guidance range we provided at the beginning of the year. Moving to our newly acquired HYA business. The team continues to deliver robust results with strong growth in net sales and active monthly subscribers.

[Jim Brown, CEO & President at USANA Health Sciences]

Hyatt continues to see increasing subscriber adoption of both its core product offering as well as new products. For example, Kitts Daily Greens, which was launched in the third quarter of twenty twenty four, has continued to sell at a higher than expected pace. We expect this year over year growth and Hyatt's momentum to continue as the management team executes its plans to launch several new products this year, unveil another strategic partnership and expand to additional channels. We're confident in the continued growth of the business and are proud to be reaching a new customer demographic in children's health and wellness. Before opening the call for questions, I'd like to provide some thoughts on USANA's position as it relates to tariffs and other trade related actions by The U.

[Jim Brown, CEO & President at USANA Health Sciences]

S. And its trading partners around the world. The impact of potential trade policies and tariffs remain highly uncertain at this time. As such, we have not reflected any potential impact in our financial guidance. As a reminder, we manufacture in China for our China market and manufacture for the rest of the world here in The U.

[Jim Brown, CEO & President at USANA Health Sciences]

S. While this structure does afford some insulation from recently enacted tariffs, we do source certain raw materials from various markets around the globe and therefore have exposure to tariffs. Our primary focus for now is on the potential tariff impact associated with importing certain raw materials from China into The U. S. And importing certain raw materials from The U.

[Jim Brown, CEO & President at USANA Health Sciences]

S. Into China. Our team responsible for supply chain management has proactively built inventory over the last several quarters to mitigate tariff exposure and has continued to explore alternate sourcing relationships. Our team will continue to evaluate and pursue these strategies to address the potential impact of tariffs and emerging trade policies as they evolve. And we plan to provide additional information as we gain greater visibility.

[Jim Brown, CEO & President at USANA Health Sciences]

With that, I'll now ask the operator to please open the lines for questions.

[Operator]

Thank you. And at this time, we will conduct our question and answer session. Our first question comes from Andrew Lebiedzinski with Sidoti and Company. Please state your question.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

Yes. Good morning, everyone, and thanks for taking the questions. So first, China and South Korea, the post net sales and active customer count increases on a sequential basis. You guys talked about incentive offerings helping those out at the start of the year. So just curious as to what your plans are for additional incentives in these countries and elsewhere.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

How do you guys think about that as far as that's concerned? We'd love to hear your thoughts on that.

[Brent Neidig, CCO & MD - China at USANA Health Sciences]

Sure thing. Hey, Anthony, it's Brent here. Good morning.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

Good morning.

[Brent Neidig, CCO & MD - China at USANA Health Sciences]

China did have a good quarter. It was helped at the beginning of the year. We had a couple of product promotions that took place before Chinese New Year and those were all very, very successful and which helped drive the quarter the quarterly results. We're always opportunistic and we're always looking at promotions when they're going to make the most sense, how we can drive the best value for our distributors and customers around the world. So we are always going to continue to evaluate promotions and throughout every one of the quarters, the rest of this year we do have promotional incentives planned.

[Brent Neidig, CCO & MD - China at USANA Health Sciences]

So that's currently on the docket. Korea, it also was a good first quarter relative to Q4 of last year. I think in both of those markets, we're starting to see some really positive momentum, especially with our event that we had in China during the first quarter first part of the second quarter. Really great event that we had there in Nanjing with 13,000 attendees. Just really strong momentum and great things that we're seeing there.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

That's encouraging to hear. Thanks for that. And then with respect to Chaya, so you talked about the seasonality of the business, which is understandable. As far as the new product launches that are planned for this year, can you share some more specifics about the timing and kind of what's embedded in your guidance?

[Doug Hekking, Chief Financial Officer at USANA Health Sciences]

Yes. They have plans. I think the timing, you'll see that systematically kind of happen over the year. They have a right now there's a plan for pretty meaningful launch of kind of a new relationship at the May. But the team is always bringing different ideas and really is a point to go back and engage a broader funnel and engage more customers in acquiring those customers.

[Doug Hekking, Chief Financial Officer at USANA Health Sciences]

And so this is probably the primary part of their growth strategy right now is on product innovation and broadening that product offering out. You also see them exploring channel opportunities and really kind of evaluating kind of that experience with the customer which is I think been a real strength of theirs. And so I think we see continuation of that but it really is continues to be focused on the children's health and wellness category and that will be squarely in focus as they move forward here. And so I think there's quite a few opportunities they're encouraged by and some that may play a little bit different potentially in different channels than what they currently operate.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

Thanks, Doug. And then so now that you've had a higher for four months, do you guys have any updated thoughts on the synergy opportunities?

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

Yes. This is Walter. Yes, we've been working with Hyatt especially operationally because it's one of our strengths. We do manufacturing. We understand supply chain real well and we can really help them with that.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

So there are definitely synergies. There are a lot of things we're helping with them with IT. So yes, lots of projects going on right now where both teams are collaborating.

[Jim Brown, CEO & President at USANA Health Sciences]

Yes. We're taking this very a very systematic approach. The one thing that we have to be careful with is with a lot of opportunities for synergies, we don't want to overwhelm the Hyatt team and somehow distract them from their strategy for 2025 and 2026. So we're taking a very measured approach when we're looking at ways to improve them from an operational standpoint.

[Doug Hekking, Chief Financial Officer at USANA Health Sciences]

Yes. And I would say many of these things, Anthony, think the yields and the benefits you're not going to see on an immediacy basis, you'll see that kind of systematically layered in there as we do that. So we're really focused on things that will be additive and beneficial to both parties.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

Got it. That makes sense. And can you give us any update on India, how that's progressing?

[Brent Neidig, CCO & MD - China at USANA Health Sciences]

Yes. India is still a promising market for us. We still have high expectations and high hopes for it to become a very solid stable market for us in the future. It still is a slow roll, as we've mentioned in previous quarters. Our Chief Sales Officer is over there currently right now, meeting with our leaders and our leadership team over there.

[Brent Neidig, CCO & MD - China at USANA Health Sciences]

We have a lot of energy and emphasis that's being placed on that market to see it start to pick up its growth momentum. So we have a few plans in place and we're optimistic about where it's going to go.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

Got you. Right. Thanks, Brent. And then lastly for me, as far as the potential tariff impact, so I know you guys brought in some additional inventories to try to get ahead of that. So do you think what you have done so far, is this for one quarter out as far as the higher inventory?

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

Or is it more than that? I mean, just trying to obviously, it's still a very fluid and dynamic environment as it relates to tariffs. But just maybe if you could expand on that as far as like the level of inventory that you have for raw materials, is it good like for how long of a period of time should that be good for?

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

This is Walter. As far as raw material, we've built that up especially for our nutritional products because that's a lion's share of our revenue, a lot of it comes from there. We in February, we started recognizing that there might be tariffs coming. So we bought ahead. But again, the real issue I mean, it's a little bit what Jim said earlier.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

We don't have a ton of inventory coming for instance from China to The U. S. It's 6% of our overall raw materials that come from China. So we've worked on that for the last four years. The impact isn't as bad, but it's still there's still money there to be made.

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

And so we want to make sure we had inventory ready. We've also been manufacturing finished goods and getting them out to markets just again to prepare for tariffs.

[Jim Brown, CEO & President at USANA Health Sciences]

Yes. And over the last few years too, Walter and the supply chain team and we've mentioned this has really worked on multiple sources and they can come from different geographic locations as well. So that has also lessened the impact some.

[Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC]

That makes a lot of sense. Well, you very much guys and best of luck.

[Jim Brown, CEO & President at USANA Health Sciences]

Thank you.

[Operator]

Thank you. Our next question comes from Ivan Feinseth with Tigress Financial Partners. Please state your question.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

Hi. Congratulations on the great start to the year and the success with the HYA acquisition.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

just starting with China, what have been some of the new products that were launched there and the reception that you're getting? And what do you see as some of the new categories that you're going to be launching?

[Brent Neidig, CCO & MD - China at USANA Health Sciences]

Sure thing, Ivan. So at our event in the second quarter, so the first part of the second quarter there in Nanjing, we only had a couple of new products that were launched. One was a new chewable calcium product for children and that was really well received. It beat our forecast. And then a couple of other products that were launched through our cross border e commerce channel.

[Brent Neidig, CCO & MD - China at USANA Health Sciences]

They were some of our existing USANA Nutritionals products that we were then introducing into China for the first time and those were also very well received. So at the beginning of the year, it is more of a slow roll. As we've talked about in the past, the product introductions and enhancements that are going to take place will accelerate in the back half of the year. So that is going to be the same for here in The United States and in China and in our other markets around the world. So we expect in the second half of the year you should see a greater acceleration of new product introductions.

[Jim Brown, CEO & President at USANA Health Sciences]

Yes. As you know from the past that we have our international convention in August and we usually use big meetings like that like for example what Brent was talking about in China as launching point. So when we talk about the second half, lot of it will come around that mid August timeframe.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

Okay. And then for my big question is that there are a lot of competing products on the market that contain a lot of bad ingredients. And now what do you think your opportunity is as RFK starts to implement the elimination of a lot of these colors, dyes, artificial ingredients and you tend to lean toward a more natural product. How do you feel that the opportunity how do you feel that that will create an opportunity for you?

[Doug Hekking, Chief Financial Officer at USANA Health Sciences]

Ivan, this is Doug. I think we've always been well positioned just from the ethos of the company to capitalize on that. And I think one of the things Brent and his team have really done is focused a lot more on gauging the story and telling the differentiation. And I think as we continue to perfect that message to get it out there that resonates at a greater and greater level. And so yes, I think it's an opportunity for us.

[Doug Hekking, Chief Financial Officer at USANA Health Sciences]

It's something that we've always done. We've always had that as part of our identity and have some of those things come to light I think provides us ability to tell more differentiated story moving forward.

[Jim Brown, CEO & President at USANA Health Sciences]

Yes. It actually goes into Hyah as well. They're in the same boat, very clean products. So this again is an opportunity for both Hyah and USANA.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP]

Yes. Thank you. Congratulations again and wish you a great year.

[Jim Brown, CEO & President at USANA Health Sciences]

Sure. Thanks, Ivan.

[Doug Hekking, Chief Financial Officer at USANA Health Sciences]

Thanks, Ivan.

[Operator]

Thank you. And there appears to be no additional questions at this time. I'll hand the floor back to Andrew Masuda for closing remarks.

[Andrew Masuda, Director of Investor Relations at USANA Health Sciences]

Thanks for your questions and participation on today's conference call. If you have any remaining questions, please feel free to contact Investor Relations at (801) 954-7210.

[Operator]

Thank you. This concludes today's call. All parties may disconnect. Have a good day.

Participants

Executives

• Andrew Masuda, Director of Investor Relations
• Jim Brown, CEO & President
• Brent Neidig, CCO & MD - China
• Doug Hekking, Chief Financial Officer
• Walter Noot, Chief Operating Officer

Analysts

• Anthony Lebiedzinski, Senior Equity Research Analyst at Sidoti & Company, LLC
• Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners LLP